Barbara Burtness, MD

Articles

Dr Burtness on Subgroup Outcomes for Transoral Surgery and Risk-Based Radiation in HPV+ Oropharynx Cancer

June 14th 2024

Barbara Burtness, MD, discusses findings from a subgroup analysis from the phase 2 E3311 trial in HPV-associated oropharynx cancer.

Dr Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer

May 3rd 2023

Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.

Dr. Burtness on the Efficacy of Checkpoint Inhibitors in Head & Neck Cancer

June 29th 2021

Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.

Dr. Burtness on the Effectiveness of Immunotherapy in Head and Neck Cancers

March 31st 2020

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

Dr. Burtness on the Future of Immunotherapy in Head and Neck Cancer

August 29th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the future of immunotherapy in head and neck cancer.

Dr. Burtness on the Use of Biomarkers in Metastatic HNSCC

April 29th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology) Disease Aligned Research Team Leader, Head and Neck Cancers Program co-director, Developmental Therapeutics Research Program of Yale Cancer Center, discusses the use of biomarkers in metastatic head and neck squamous cell carcinoma.

Dr. Burtness on Promise of Frontline Pembrolizumab in Metastatic HNSCC

March 30th 2019

Dr. Burtness on the Benefit of Pembrolizumab in Head and Neck Cancer

December 1st 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses the benefit of pembrolizumab (Keytruda) as a treatment for patients with recurrent metastatic head and neck squamous cell carcinoma.

Dr. Burtness on Frontline Immunotherapy in Head and Neck Cancer

November 1st 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses frontline immunotherapy in head and neck cancer.

Dr. Burtness on Findings of KEYNOTE-048 in Head and Neck Cancer

October 22nd 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses findings from the KEYNOTE-048 in head and neck squamous cell carcinoma (HNSCC).

Dr. Burtness on Challenges Facing Immunotherapy in Head and Neck

August 7th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Dr. Burtness on Immunotherapy Resistance in Head and Neck Cancer

July 27th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.

Dr. Burtness on Combinations of Immunotherapy in Head and Neck Cancer

July 21st 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

July 19th 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Dr. Burtness on Evolution of Molecular Testing in Head and Neck Cancer

May 3rd 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the evolution of molecular testing in head and neck cancer.

Dr. Burtness on Treatment Approaches in HPV-Positive Head and Neck Cancer

December 27th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.

Dr. Burtness on the Use of Immunotherapy After Chemoradiation in Head and Neck Cancer

December 15th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.

Dr. Burtness on Immunotherapy and Chemotherapy in Head and Neck Cancer

October 12th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the potential benefits of using immunotherapy and chemotherapy together in head and neck cancer.

Dr. Burtness on Ongoing Trials of Immunotherapy in Head and Neck Cancer

September 21st 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses some of the ongoing trials currently examining the use of immunotherapy to treat patients with head and neck cancer.

Promising Immuno-Oncology Approaches in the Management of Squamous Cell Carcinoma of the Head and Neck

January 27th 2016

Substantial evidence exists that a subset of squamous cell cancers of the head and neck display phenotypic changes that predict activity for immune checkpoint inhibitors.